MINT-RIVASTIGMINE CAPSULE

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)

可用日期:

MINT PHARMACEUTICALS INC

ATC代码:

N06DA03

INN（国际名称）:

RIVASTIGMINE

剂量:

1.5MG

药物剂型:

CAPSULE

组成:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5MG

给药途径:

ORAL

每包单位数:

56

处方类型:

Prescription

治疗领域:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

產品總結:

Active ingredient group (AIG) number: 0140521001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2017-06-19

产品特点

PRODUCT MONOGRAPH
PR
MINT-RIVASTIGMINE
1.5 mg, 3 mg, 4.5 mg, 6 mg Rivastigmine
(supplied as Rivastigmine Hydrogen Tartrate)
Capsules
Mint Standard
Cholinesterase Inhibitor
Mint Pharmaceuticals Inc. Date of Revision: December 22, 2016
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6
Submission Control No: 200803
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
............................................................................
3
CONTRAINDICATIONS
..............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
............................................................................................
11
DRUG INTERACTIONS
............................................................................................
25
DOSAGE AND ADMINISTRATION
...........................................................................
26
OVERDOSAGE
.........................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 29
STORAGE AND STABILITY
......................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 32
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
PHARMACEUTICAL INFORMATION
........................................................................
33
CLINICAL TRIALS
.....................................................................................................
34
DETAILED PHARMACOLOGY
..........................................................................